Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
McKesson
Express Scripts
Colorcon
Dow

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

CAMPATH Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for CAMPATH

Identify potential brand extensions & biosimilar entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1
American College of SurgeonsPhase 1

See all CAMPATH clinical trials

Recent Litigation for CAMPATH

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all CAMPATH litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Forty Seven, Inc.2016-08-08
Forty Seven, Inc.2016-08-05

See all CAMPATH litigation

Pharmacology for CAMPATH

Company Disclosures: US Patents for CAMPATH

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2014-08-05 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial British Technology Group Limited (London, GB) 2015-12-08 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for CAMPATH

These patents were identified by searching patent claims

Supplementary Protection Certificates for CAMPATH

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
CA 2016 00026 Denmark   Start Trial PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
16C0023 France   Start Trial PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916
300967 Netherlands   Start Trial PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: EU/1/18/1297 20180827
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Mallinckrodt
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.